Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL

Web Exclusives - FDA Updates, In the News
Yvette Florio Lane

On June 10, 2019, the US Food and Drug Administration (FDA) granted accelerated approval to the novel antibody-drug conjugate polatuzumab vedotin-piiq (Polivy; Genentech) in combination with bendamustine plus rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least 2 previous therapies. This is the first chemoimmunotherapy regimen approved for use in patients with DLBCL who are ineligible for hematopoietic stem-cell transplantation.1,2

Polatuzumab vedotin-piiq attaches to a chemotherapy drug and binds to the CD79b protein, which is found exclusively in B-cells. Once bound to CD79b, polatuzumab vedotin-piiq releases the chemotherapy drug into the B-cells.

“Antibody-drug conjugates are an emerging class of targeted immunotherapies for cancer. This type of therapy, unlike traditional chemotherapy, is intended to target specific cells,” said Richard Pazdur, MD, Director, Oncology Center of Excellence, and Acting Director, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, FDA, Silver Spring, MD.

The accelerated approval was based on results from the phase 1B/2 GO29365 clinical trial, which included 80 patients who were randomized to receive polatuzumab vedotin-piiq with bendamustine plus rituximab or bendamustine plus rituximab alone.2 The complete response rate was 40% in patients who were treated with polatuzumab vedotin-piiq plus bendamustine plus rituximab compared with 18% in those treated with bendamustine plus rituximab alone.2 Of the 25 patients who achieved a partial or complete response to polatuzumab vedotin-piiq plus bendamustine plus rituximab, 16 (64%) had a duration of response of at least 6 months and 12 (48%) had a duration of response of at least 12 months.2

“Today’s approval of Polivy provides an alternative option for patients in whom multiple treatments have not worked,” said Dr Pazdur.

The most common adverse reactions associated with polatuzumab vedotin-piiq plus bendamustine plus rituximab include neutropenia, thrombocytopenia, and anemia; peripheral neuropathy; fatigue; diarrhea; fever; decreased appetite; and pneumonia. Infusion-related reactions, low blood counts, and fatal and/or serious infections are possible with this treatment and should be monitored. Other serious and potentially fatal adverse events, including tumor lysis syndrome, hepatotoxicity, and progressive multifocal leukoencephalopathy, may also occur.1

Female patients in their reproductive years should use effective contraception and should avoid pregnancy for 3 months after taking their last dose of polatuzumab vedotin-piiq. Women who are pregnant or breastfeeding should not take polazutumab vedotin-piiq because it may cause harm to a developing fetus or newborn baby.1

More than 18,000 people in the United States are diagnosed with DLBCL each year. Although it is curable, the relapse rate associated with DLBCL is approximately 30% to 40%.1

The FDA grants conditional approval to a drug or device that fills an unmet medical need for a serious condition through its Accelerated Approval Program. Continued approval for this indication requires verification of clinical benefit through a confirmatory trial. The FDA’s Priority Review designation is granted to drugs thought to have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention, or diagnosis of a serious disease. The FDA also gave polatuzumab vedotin-piiq orphan drug status.


References

  1. US Food and Drug Administration. FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma. June 10, 2019. www.fda.gov/news-events/press-announcements/fda-approves-first-chemoimmunotherapy-regimen-patients-relapsed-or-refractory-diffuse-large-b-cell. Accessed June 10, 2019.
  2. Business Wire. FDA grants Genentech’s Polivy accelerated approval for people with previously treated aggressive lymphoma. June 10, 2019. www.businesswire.com/news/home/20190610005588/en. Accessed June 10, 2019.
Related Items
Regenerative Medicine Advanced Therapy Designation Granted to ADP-A2M4 for Synovial Sarcoma
Web Exclusives published on December 11, 2019 in FDA Updates, In the News, Synovial Sarcoma
FDA Grants Priority Review to Keytruda for Patients with High-Risk, Non–Muscle-Invasive Bladder Cancer
Web Exclusives published on December 3, 2019 in Bladder Cancer, FDA Updates, Immunotherapy
Inrebic Receives FDA Approval for Adults with Myelofibrosis
Web Exclusives published on December 2, 2019 in FDA Updates
FDA Approved Erleada for Metastatic Castration-Sensitive Prostate Cancer
Web Exclusives published on December 2, 2019 in FDA Updates
Keytruda plus Lenvima Combo FDA Approved for Advanced Endometrial Carcinoma with No MSI-H or dMMR Tumors
Web Exclusives published on December 2, 2019 in FDA Updates
FDA Approves Adakveo to Reduce Vaso-Occlusive Crises in Patients with Sickle-Cell Disease
Web Exclusives published on November 25, 2019 in FDA Updates, In the News
November 25, 2019 – Oncology News & Updates
Web Exclusives published on November 25, 2019 in FDA Updates, In the News, Leukemia, Lung Cancer, Lymphoma
November 18, 2019 — Oncology News & Updates
Web Exclusives published on November 18, 2019 in Drug Updates, FDA Updates, Hepatocellular Carcinoma, In the News, Lymphoma
November 11, 2019 — Oncology News & Updates
Web Exclusives published on November 11, 2019 in FDA Updates, In the News
Zejula Receives FDA Approval for HRD-Positive Advanced Ovarian Cancer
Web Exclusives published on November 7, 2019 in FDA Updates, Ovarian Cancer
Last modified: June 12, 2019